AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant Mice  by Li, Yu et al.
Cell Metabolism
ArticleAMPK Phosphorylates and Inhibits SREBP Activity
to Attenuate Hepatic Steatosis and Atherosclerosis
in Diet-Induced Insulin-Resistant Mice
Yu Li,1 Shanqin Xu,1 Maria M. Mihaylova,2,3 Bin Zheng,4 Xiuyun Hou,1 Bingbing Jiang,1 Ogyi Park,5 Zhijun Luo,1
Etienne Lefai,6 John Y.-J. Shyy,7 Bin Gao,5MichelWierzbicki,8 Tony J. Verbeuren,8 Reuben J. Shaw,2,3 Richard A. Cohen,1
and Mengwei Zang1,*
1Department of Medicine, Vascular Biology Section, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston,
MA 02481, USA
2Howard Hughes Medical Institute
3Molecular and Cell Biology Laboratory
The Salk Institute for Biological Studies, La Jolla, CA 92037, USA
4Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA
5Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA
6Lyon University, INSERM U1060, INRA U1235, CarMeN Laboratory, University Lyon-1, F- 69600 Oullins, France
7Division of Biomedical Sciences, University of California, Riverside, Riverside, CA 92093, USA
8Institut de Recherche Servier, 92150 Suresnes, France
*Correspondence: mwzang1@bu.edu
DOI 10.1016/j.cmet.2011.03.009SUMMARY
AMPK has emerged as a critical mechanism for
salutary effects of polyphenols on lipid metabolic
disorders in type 1 and type 2 diabetes. Here we
demonstrate that AMPK interacts with and directly
phosphorylates sterol regulatory element binding
proteins (SREBP-1c and -2). Ser372 phosphoryla-
tion of SREBP-1c by AMPK is necessary for inhibi-
tion of proteolytic processing and transcriptional
activity of SREBP-1c in response to polyphenols
and metformin. AMPK stimulates Ser372 phosphor-
ylation, suppresses SREBP-1c cleavage and nuclear
translocation, and represses SREBP-1c target gene
expression in hepatocytes exposed to high glucose,
leading to reduced lipogenesis and lipid accumula-
tion. Hepatic activation of AMPK by the synthetic
polyphenol S17834 protects against hepatic steato-
sis, hyperlipidemia, and accelerated atherosclerosis
in diet-induced insulin-resistant LDL receptor-
deficient mice in part through phosphorylation of
SREBP-1c Ser372 and suppression of SREBP-1c-
and -2-dependent lipogenesis. AMPK-dependent
phosphorylation of SREBP may offer therapeutic
strategies to combat insulin resistance, dyslipide-
mia, and atherosclerosis.
INTRODUCTION
The metabolic defects of obesity and type 2 diabetes, character-
izedby insulin resistance, nonalcoholic fatty liver disease, anddys-
lipidemia, lead to an increased risk of cardiovascular disease (Se-
menkovich, 2006). Sterol regulatory element binding protein376 Cell Metabolism 13, 376–388, April 6, 2011 ª2011 Elsevier Inc.(SREBP) is a key lipogenic transcription factor that is nutritionally
regulated by glucose and insulin (Horton et al., 2002; Goldstein
andBrown, 2008). SREBP-1cpreferentially regulates the lipogenic
process by activating genes involved in fatty acid and triglyceride
synthesis, whereas SREBP-2 primarily controls cholesterol
homeostasisbyactivatinggenes required for cholesterol synthesis
and uptake. Both SREBP-1c and -2 isoforms are synthesized as
precursor proteins that are inserted into theendoplasmic reticulum
(ER) membrane. The precursor of SREBPmigrates from the ER to
the Golgi and undergoes sequential proteolytic processing to
release the transcriptionally active N-terminal basic-helix-loop-
helix (bHLH)-Zip domain. Once the mature, active nuclear form
of SREBP is translocated into the nucleus, it binds to sterol regula-
tory element (SRE), present in the promoters of its own and target
genes, and activates the transcription of SREBP-responsive
genes, thereby promoting the lipogenic process in the liver. The
dysregulation of SREBP-1c has been implicated in the pathogen-
esis of hepatic steatosis, dyslipidemia, and type 2 diabetes (Ra-
ghow et al., 2008; Browning and Horton, 2004).
Our recent studies demonstrate that resveratrol, a natural poly-
phenol present in red wine, and S17834, a synthetic polyphenol,
potently and persistently stimulate the kinase activity of AMPK,
an energy sensor that maintains cellular energy homeostasis
(Kahn et al., 2005), in human HepG2 hepatocytes and in type 1
diabetic mouse livers (Zang et al., 2006). Other studies have
also shown that resveratrol activates hepatic AMPK and amelio-
rates insulin sensitivity in high fat-fed mice (Baur et al., 2006) and
that the metabolic effects of resveratrol are abrogated in
AMPKa1- or a2-deficientmice (Umet al., 2010). AMPK activation
bypolyphenols canexplain their beneficial effects onhepatic lipid
accumulation, hyperlipidemia, and atherogenesis in type 1 dia-
betic LDL receptor deficient (LDLR/) mice (Zang et al., 2006).
Previous studies have shown an inverse correlation between
AMPK and SREBP-1c activities in hepatocytes and in livers of
refed mice and ethanol-fed mice (Zhou et al., 2001; Yang et al.,
2009; Foretz et al., 2005; You et al., 2004). However, it is largely
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lipid homeostasis, especially in the insulin-resistant state. An un-
answered but important question is how elevated sterol and
cholesterol levels, a condition that is known to negatively regulate
SREBP proteolytic cleavage, lead to the dysregulation of SREBP
and lipogenesis in type 2 diabetes.
This study provides the molecular insight into the mechanism
by which AMPK inhibits cleavage and transcriptional activation
of SREBP via direct phosphorylation. SREBP-1c and -2, but
not SREBP-1a, are characterized as conserved substrates of
AMPK. AMPK is sufficient and necessary for the suppression
of SREBP-1c proteolytic processing, nuclear translocation,
and gene expression of target lipogenic enzymes in response
to AMPK activators, such as polyphenols and metformin, in
primary hepatocytes or in HepG2 cells under conditions
mimicking in vivo hyperglycemia and hyperinsulinemia. The
AMPKa subunit strongly associates with and highly phosphory-
lates the precursor and nuclear forms of SREBP-1c or -2.
SREBP-1c Ser372 phosphorylation is required for AMPK activa-
tors to inhibit SREBP-1c cleavage and prevent SREBP-1c gene
autoregulation in a SRE-dependentmanner. Furthermore, AMPK
activation in high-fat/high-sucrose (HFHS) diet-induced insulin-
resistant LDLR/ mice treated with S17834 stimulates hepatic
SREBP-1c phosphorylation, decreases cleavage of SREBP-1c
and -2, and reduces expression of key target lipogenic enzymes,
which in turn ameliorates insulin resistance, hepatic steatosis,
hyperlipidemia, and atherosclerosis. Conversely, AMPK-depen-
dent phosphorylation of SREBP-1c Ser372 is impaired in the liver
of insulin-resistant mice. These studies (1) characterize AMPK as
a direct upstream kinase that binds to and phosphorylates
SREBP-1c and -2; inhibits their cleavage, nuclear translocation,
and transcriptional activity; and ultimately suppresses hepato-
cyte lipogenesis; (2) illustrate that the integrated inhibition of
AMPK and activation of SREBP-dependent hepatic lipogenesis
are implicated in the development of insulin resistance; and (3)
reveal that Ser372 phosphorylation of SREBP-1c by pharmaco-
logical AMPK activators is of key therapeutic importance in
preventing fatty liver disease, dyslipidemia, and atherosclerosis
in type 2 diabetes.
RESULTS
The Synthetic Polyphenol S17834 Stimulates AMPK
Activity and Ameliorates Systemic Insulin Resistance
and Hepatic Steatosis in Diet-Induced Obese
LDLR–/– Mice
Unlike the apolipoprotein (Apo) E/ mouse model, the athero-
sclerotic LDLR/ mouse model is more susceptible to devel-
oping hepatic steatosis, insulin resistance, hyperlipidemia, and
enhanced atherosclerotic plaque when fed a type 2 diabetogenic
diet composed of high fat, high sucrose (HFHS) (Schreyer et al.,
2002). Expanding upon our studies of the role of a polyphenolic
AMPK activator in type 2 diabetes, LDLR/ mice were placed
for 16 weeks on a normal chow diet, a HFHS diet, and a HFHS
diet supplemented with S17834 (HFHS+S17834, 130 mg/kg/
day). The efficacy and lack of hepatotoxicity of S17834 at the
dosage used have been previously established (Zang et al.,
2006). As shown in Figures 1A–1Eand Figure S1 (available online),
S17834 caused a modest but statistically significant decrease inCblood glucose and a large reduction in plasma insulin and the
calculated HOMA-IR. The body weight gain of mice after 8 and
16 weeks of S17834 treatment was lowered by 19% and 25%,
respectively. The heart weight, ratio of heart weight to body
weight, and blood pressure were not significantly different in the
three groups (Table S1). HFHS-fed mice exhibited a uniformly
pale fatty liverandhepatomegaly, and thesepathological changes
were reversed by S17834. Administration of S17834 eliminated
excess fat accumulation in hepatic intracellular vacuoles, as
determined by hematoxylin and eosin (H&E) staining and oil red
Ostaining.These results indicate thatS17834effectively improves
diet-induced obesity, insulin resistance, and hepatic steatosis.
To investigate whether AMPK might be responsible for the
protective effects of S17834, hepatic AMPK activity was
assessed by determining the phosphorylation state of AMPK
and acetyl-CoA carboxylase (ACC), a well-characterized target
of AMPK. Hepatic phosphorylation of AMPK and ACC was
decreased by 40% in HFHS-fed mice and substantially
restored by S17834. No significant changes in endogenous
AMPKa andACCwere evident (Figures 1F and1GandFigure 2F).
AMPK Activation by S17834 Suppresses the
Accumulation of Nuclear SREBP-1c and -2, Represses
Expression of Their Target Genes, and Ameliorates
Aberrant Lipogenesis in the Liver of Insulin-Resistant
LDLR–/– Mice
To test the hypothesis that the insulin-sensitive phenotype of
S17834-treated mice might be due to the suppression of hyper-
active SREBP in diabetic mouse livers, we first determined
SREBP-1 and -2 cleavage processing, as reflected by the
amounts of the precursor (125 kDa) and nuclear active forms
(68 kDa). The accumulation of nuclear SREBP-1 in the liver of
insulin-resistant mice was markedly reduced by S17834. No
significant change in the SREBP-1 precursor levels was noted
among the three groups. Interestingly, S17834 also reduced the
amounts of cleaved SREBP-2 that were a 2.8-fold increase in
HFHS-fed LDLR/ mice, which was accompanied by slight
changes in SREBP-2 precursor (Figures 2A–2C). Because
mRNA levels for SREBP were upregulated by nuclear SREBP
via a feed-forward mechanism (Horton et al., 2002), the mRNA
amounts of SREBP-1c and SREBP-2, two major isoforms in the
liver, and of SREBP-1a, the less abundant isoform, were further
determined by real-time PCR. The mRNA levels of hepatic
SREBP-1c and -2 were significantly increased by the HFHS
diet, and this effect was completely reversed by S17834.
Conversely, SREBP-1a mRNA was not sensitive to either hyper-
insulinemia or S17834 (Figure 2D). Thus, the changes inSREBP-1
protein in mouse livers may represent SREBP-1c, although the
antibody used for immunoblots recognizes both SREBP-1c and
SREBP-1a isoforms. These results indicate that AMPK downre-
gulates hepatic SREBP-1c and -2 processing and thereby
prevents the feed-forward transcription of their own genes.
To determine the functional consequences of suppressed
nuclear SREBP by AMPK, gene expression of key target
enzymes of SREBP-1c and -2 in the liver was assessed by
qRT-PCR. Consistent with dynamically altered nuclear SREBP-
1c, the expression of enzymes involved in fatty acid and triglyc-
eride synthesis, including acetyl-CoA carboxylase 1 (ACC1),
fatty acid synthase (FAS), and stearoyl CoA desaturase 1ell Metabolism 13, 376–388, April 6, 2011 ª2011 Elsevier Inc. 377
Figure 1. A Synthetic Polyphenol, S17834, Stimulates AMPK Activity and Protects against Insulin Resistance and Hepatic Steatosis
in High-Fat, High-Sucrose Diet-Fed LDL Receptor-Deficient Mice
(A–C) Administration of S17834 for 16 weeks effectively improves insulin resistance in mice fed the type 2 diabetogenic diet (HFHS diet). Plasma insulin levels,
blood glucose, and calculated HOMA-IR were assessed in mice fed a normal chow diet (n = 10–15), a HFHS diet (n = 30), and a HFHS diet supplemented with
S17834 (HFHS + S17834, n = 30). The data are presented as the mean ± SEM. *p < 0.05, versus normal diet mice; #p < 0.05, versus HFHS-fed mice.
(D and E) Representative gross morphology of the mouse livers, H&E staining and oil red O staining of liver sections.
(F) AMPK activity is suppressed by HFHS diet and restored by S17834 in the liver of insulin-resistant mice.
(G) Densitometric quantification of the phosphorylation of AMPK and ACC. The data are presented as the mean ± SEM, n = 8. *p < 0.05, versus normal diet mice;
#p < 0.05, versus HFHS-fed mice.
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reduced by S17834 to nearly normal levels. Similar to decreased
nuclear SREBP-2, the elevation in mRNAs encoding two key
enzymes of cholesterol biosynthesis, 30-hydroxylmethyl glutaryl
coenzyme A synthease (HMGCS) and 30-hydroxylmethyl glutaryl
coenzyme A reductase (HMGCR), was prevented by S17834 in
insulin-resistant mice (Figure 2E). Moreover, decreased protein
expression of FAS and HMGCR by S17834 was further
confirmed by immunohistochemical analysis of liver sections
(Figures 2F–2I), as described in the clinical setting (Dorn et al.,
2010). Consequently, S17834 caused an 40%–50% decrease
in hepatic triglyceride and cholesterol contents, which was well
correlated with the reduction in nuclear SREBP-1 and -2-depen-
dent lipogenic enzymes. These data indicate that suppression of
SREBP by S17834 ameliorates hepatic steatosis at least in part378 Cell Metabolism 13, 376–388, April 6, 2011 ª2011 Elsevier Inc.by inhibiting nuclear SREBP autoloop regulation and reducing its
target gene transcription.
Hepatic AMPK Activation and SREBP Suppression by
S17834 Attenuate Hyperlipidemia and Accelerated
Aortic Atherosclerosis in Insulin-Resistant LDLR–/– Mice
Plasma total cholesterol and triglyceride levels were persistently
decreased by approximately 30% in insulin-resistant mice after
S17834 treatment (Figures 3A and 3B). Consistently, HFHS-fed
mice exhibited dramatically higher plasma very low density lipo-
protein (VLDL) and IDL/LDL cholesterol levels, due to the lack of
themajor clearance of plasma VLDL/LDL-cholesterol in LDLR/
mice. The accumulation of VLDL/LDL cholesterol was decreased
by S17834 without significant alterations in plasma high-density
lipoprotein (HDL) cholesterol (Figures 3C and 3D). These data
Figure 2. AMPK Activation by S17834
Attenuates the Proteolytic Processing of
SREBP-1 and SREBP-2, Inhibits Expression
of Their Target Lipogenic Enzymes, and
Reduces Lipid Accumulation in the Liver of
Insulin-Resistant LDLR–/– Mice
(A) The mature, active nuclear form of hepatic
SREBP-1 is increased in HFHS-fed mice, and the
increase is completely blocked by S17834 treat-
ment. P and N denote the precursor (125 kDa)
and cleaved nuclear (68 kDa) forms of SREBP-1.
(B) Enhanced SREBP-2 processing by HFHS diet
is reduced in the liver of S17834-treated mice.
(C) Densitometric quantification of cleaved forms of
hepatic SREBP-1 and -2. The data are presented as
the mean ± SEM, n = 4–8. *p < 0.05, versus normal
diet mice; #p < 0.05, versus HFHS-fed mice.
(D and E) The transcription of genes involved in
triglyceride and cholesterol biosynthesis is
decreased in the liver of S17834-treated mice.
The mRNA amounts of genes encoding SREBP-
1a, SREBP-1c, and SREBP-2 (D), as well as genes
encoding ACC1, FAS, SCD1, HMGCS, and
HMGCR (E) in the mouse livers, were determined
by real-time RT-PCR.
(F–H) S17834 decreases the protein expression of
lipogenic enzymes including FAS and HMGCR in
livers of HFHS diet-fed mice. The strong staining
for FAS and HMGCR was primarily located in
hepatocytes around the central and portal veins of
the liver of HFHS diet-fed mice. The horizontal
bars represent average staining intensity.
(I) S17834 treatment inhibits lipid accumulation in
the liver of HFHS-fedmice. The data are presented
as the mean ± SEM, n = 7–8. *p < 0.05, versus
normal dietmice; #p<0.05, versusHFHS-fedmice.
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sufficient to ameliorate dyslipidemia and to produce antiathero-
genic changes in cholesterol metabolism.
We next determined the effect of S17834 on vascular lesions in
insulin-resistant LDLR/ mice. The extent of atherosclerotic
lesions in the entire aortic tree, as determined by en face anal-
ysis, was limited to small lesions in the aortic root of LDLR/
mice fed the HFHS diet (data not shown). Therefore, atheroscle-
rotic lesion analysis was confined to cross-sections of the aortic
root. Oil red O staining revealed fatty streak lesions in the aortic
root of insulin-resistant mice, indicating early development of
atherosclerotic plaque. The aortic root lesion area showed an
4-fold increase in the HFHS-fed mice, and the elevated aortic
root lesion was reduced 60% by S17834 (Figures 3E and
3G). There was a statistically significant correlation between
plasma total cholesterol levels and advanced atherosclerotic
lesion area in HFHS-fed mice that were untreated or treated
with S17834 (R2 = 0.4732, p < 0.01) (Figure 3F). Moreover,
the protective effects of S17834 on vascular dysfunction were
evidenced by decreased expression of vascular cell adhesionCell Metabolism 13, 376–molecule-1 (VCAM-1), a molecular
marker of vascular inflammation, in the
aortic arch of HFHS-fed mice, as deter-
mined by immunohistochemical staining
(Figures 3H and 3I). Collectively, theseresults indicate that AMPK-dependent suppression of SREBP-
1c and -2 in the liver prevents hyperlipidemia and enhances
aortic atherogenesis associated with metabolic syndrome.
AMPK Suppresses SREBP-1 Cleavage Processing
and De Novo Lipogenesis in Hepatocytes
To further elucidate the mechanism by which AMPK regulates
SREBP-dependent de novo lipogenesis in hepatocytes, the
effect of AMPK activators on SREBP-1 proteolytic cleavage
and its control of lipogenic enzymes was determined in HepG2
cells under high glucose and high glucose plus insulin condi-
tions, mimicking hyperglycemia and insulin resistance in vivo.
As shown in Figures S2 and S3, S17834 and resveratrol caused
a 2-fold increase in AMPK phosphorylation in HepG2 cells
exposed to high glucose, which is consistent with our earlier
studies showing that polyphenols and metformin increased
specific AMPKa1 isoform kinase activity under the same
conditions (Zang et al., 2006). AMPK stimulation by polyphenols
also occurred in mouse hepatocytes exposed to high glucose
plus insulin. Furthermore, S17834 (10 mM) repressed the388, April 6, 2011 ª2011 Elsevier Inc. 379
Figure 3. AMPK Activation by S17834 Inhibits Accelerated Aortic Atherosclerosis and Vascular Inflammation in Insulin-Resistant LDLR–/–
Mice at Least in Part by Preventing Dyslipidemia
(A and B) Time course changes of plasma triglyceride and total cholesterol levels in mice following a 16 hr fast are presented as the mean ± SEM, n = 8–16.
(C) Lipoprotein distribution in LDLR/ mice after 16 weeks of normal diet (green), HFHS diet (red), and HFHS diet supplemented with S17834 (blue).
Pooled plasma samples for lipoprotein distribution were determined by FPLC, followed by cholesterol analysis of each fraction. Data are represented as an
average (n = 3–6) distribution of total cholesterol.
(D) The increased plasma VLDL/LDL cholesterol in HFHS-fed LDLR/mice is attenuated by S17384. Quantification of plasma VLDL/LDL cholesterol (VLDL/LDL-
C) andHDLcholesterol (HDL-C) is shown. Thedata are presented as themean±SEM, n=4–8. *p< 0.05, versus normal dietmice; #p<0.05, versusHFHS-fedmice.
(E) Quantification of atherosclerotic lesion areas in cross-sections of the proximal aorta was performed by computer-assisted image analysis. Total lesion area
per section in the entire aortic root was determined and presented as themean ± SEM, n = 8, *p < 0.05, versus normal diet mice; #p < 0.05, versus HFHS-fedmice.
(F) Linear regression analysis between plasma total cholesterol levels and aortic atherosclerotic lesions in insulin-resistant LDLR/mice. Each point represents
an individual value of one mouse.
(G) Representative oil red O staining of cross-sections of aortic root in the heart of LDLR/ mice.
(H) Expression of VCAM-1 is reduced in the aorta of S17834-treated insulin-resistant mice, as determined by immunohistochemical staining.
(I) Semiquantification analysis by ImageJ software of staining intensity of VCAM-1 in atherosclerotic plaques of ascending aortic arch of LDLR/mice is shown.
The bar graph represents the results from three separate mice in each group.
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a greater extent than resveratrol (10 mM). These results suggest
that suppression of SREBP-1 cleavage by AMPK may account
for the inhibitory effects of polyphenols on de novo fatty acid
synthesis in the liver. As shown in Figures 4A–4C, overexpres-380 Cell Metabolism 13, 376–388, April 6, 2011 ª2011 Elsevier Inc.sion of the dominant-negative AMPK (DN-AMPK) abrogated
the ability of resveratrol to repress the accumulation of nuclear
SREBP-1 in HepG2 cells. Notably, the nuclear SREBP-1 abun-
dance was increased by DN-AMPK in the absence of high
glucose. The studies with primary hepatocytes confirmed that
Figure 4. AMPK Suppresses the Cleavage
Processing and Nuclear Translocation
of SREBP-1 in Human HepG2 Cells or in
Diabetic Mouse Livers
(A and B) Overexpression of DN-AMPK abolishes
the inhibitory effect of resveratrol on accumulation
of nuclear SREBP-1 in HepG2 cells exposed to
high glucose or high glucose plus insulin. The data
are presented as themean ± SEM, n = 4. *p < 0.05,
versus normal glucose; #p < 0.05, versus high
glucose. $p<0.05, versushighglucoseplus insulin.
(C) DN-AMPK abrogates the effect of S17834 to
reduce the nuclear SREBP-1 in isolated mouse
hepatocytes. After a 24 hr period of infection with
Ad-GFP or Ad-DN-AMPK, HepG2 cells or primary
hepatocytes were incubated in serum-free DMEM
containing 5.5 mM overnight and treated for an
additional 24 hr with resveratrol or S17834 in the
presence of high glucose (30 mM) or high glucose
(30 mM) plus insulin (100 nM).
(D) Enhanced nuclear translocation of SREBP-1 in
response tohigh glucose (HG) or high glucose plus
insulin is prevented by either S17834 or metformin
in HepG2 cells. Immunoblot analysis of SREBP-1
in cytoplasmic and nuclear extracts is shown.
(E) Confocal immunofluorescence images show
SREBP-1 staining (Green) and nuclear staining
with propidium iodide (PI, red) in HepG2 cells.
(F) S17834 and metformin decrease lipid accu-
mulation in HepG2 cells exposed to high glucose
(HG) plus insulin, as reflected by oil red O staining.
(G) The nuclear translocation of SREBP-1 is
increased in the hepatocytes of insulin-resistant
mice and eliminated by S17834. A representative
confocal microscopy image of immunofluores-
cence staining of liver sections for SREBP-1
(green) and nucleus (red) is shown. Arrows
represent SREBP-1 localization in nuclei of
hepatocytes, original magnification, 360.
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dependent manner.
AMPK Inhibits SREBP-1 Nuclear Translocation and Lipid
Accumulation in HepG2 Cells Exposed to High Glucose
or in Diabetic Mouse Livers
Since SREBP-1 activity is thought to depend on its subcellular
localization (Taghibiglou et al., 2009), the effect of AMPK on
SREBP-1 subcellular distribution was assessed by immunoblot
analysis of cytosolic and nuclear extracts and confirmed by
confocal immunofluorescence microscopy. As shown in Figures
4D–4F, the proteolytic processing and nuclear fragment of
SREBP-1 were enhanced in HepG2 cells exposed to high
glucose plus insulin. Strong staining for SREBP-1 was primarily
located in both the nucleus and the ER/Golgi of these cells. In
contrast, S17834 (10 mM) eliminated the elevation in nuclear
SREBP-1 and reduced its translocation to the nuclei, compa-Cell Metabolism 13, 376–rable to those of metformin (2 mM).
Consequently, oil red O staining showed
that lipid accumulation was substantially
reduced by S17834 and metformin in
HepG2 cells. Notably, immunofluores-cent staining of liver sections showed that very strong positive
staining for SREBP-1 was primarily located in the hepatocyte
nucleus in response to hyperinsulinemia. It is worth noting that
SREBP-1 staining appeared throughout the cytoplasm and
nucleus in some hepatocytes. It is likely that all the processed
proteins did not immediately enter the hepatocyte nucleus. The
staining intensity for nuclear SREBP-1 was largely reduced in
the S17834-treated mice (Figure 4G). These findings reveal
that the proteolytic processing and nuclear translocation of
SREBP-1 are inhibited by AMPK.
AMPK Represses the Transcriptional Activity of
SREBP-1c- and SREBP-2-Dependent Lipogenic
Genes in Hepatocytes
As shown in Figures 5A and 5B and Figure S2E, mRNA levels
for SREBP-1c and FAS were increased by over 5-fold, but
there was few effects on SREBP-1a in HepG2 cells in response388, April 6, 2011 ª2011 Elsevier Inc. 381
Figure 5. AMPK Represses the Transcriptional Activity of SREBP-1c and Its Lipogenic Target Genes
(A) CA-AMPK is sufficient to suppress enhanced SREBP-1-dependent de novo lipogenic gene expression in HepG2 cells exposed to high glucose. The mRNAs
encoding SREBP-1a, -1c, and FAS were analyzed by real-time RT-PCR.
(B) AMPK is required for polyphenols to reduce mRNA levels of SREBP-1c and FAS in HepG2 cells exposed to high glucose. Data are presented as the
mean ± SEM, n = 3–4, *p < 0.05, versus normal glucose; #p < 0.05, versus high glucose.
(C) The SRE motif is responsible for AMPK to repress the transcriptional activity of SREBP-1c promoter. The proximal promoter regulatory region of human
SREBP-1c contains the cis-acting elements: two SRE elements and putative NF-Y and SP-1 sites. HepG2 cells were cotransfected with empty plasmid pGL3,
luciferase reporter plasmids containing wild-type human SREBP-1c promoters (1470/+90 and 257/+90), or the mutant reporter with disrupted SRE, together
with Renilla luciferase reporter plasmid pRL-SV40. Thirty-two hours posttransfection, cells were treated with or without polyphenols in serum-free DMEM
for 16 hr. Bars represent the mean ± SEM, n = 3–5, *p < 0.05, versus untreated cells expressing the corresponding promoter.
(D) DN-AMPK enhances the transcription activity of SREBP-1c promoter (1470/+90) and abrogates the inhibitory effect of resveratrol in HepG2 cells. Bars
represent the mean ± SEM, n = 3–5, *p < 0.05, versus untreated group. #p < 0.05, versus treatment group.
(E) AMPK/ MEFs exhibit enhanced FAS promoter activity. Bars represent the mean ± SEM, n = 3–4. *p < 0.05, versus AMPK+/+ MEFs.
(F) Suppression of FAS gene transcription in response to AICAR and S17834 is diminished by DN-SREBP-1c.
(G) AMPK suppresses FAS promoter activity in a SREBP-1c-dependent manner. Bars represent the mean ± SEM, n = 3–4. *p < 0.05, versus pcDNA control.
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fact that the SREBP-1c to -1a ratio (1:2) of human HepG2 cells
was much less than that of mouse hepatocytes (9:1) (Shimo-
mura et al., 1997). The increasing expression of the constitu-
tively active AMPK (CA-AMPK) dose-dependently decreased
the mRNA abundance of SREBP-1c and FAS, but not of
SREBP-1a. Conversely, the inhibitory effect of polyphenols to
repress SREBP-1c and FAS transcript was abolished by
DN-AMPK. These findings indicate that AMPK is sufficient and
necessary for polyphenols to suppress de novo lipogenesis382 Cell Metabolism 13, 376–388, April 6, 2011 ª2011 Elsevier Inc.through the downregulation of lipogenic gene transcription in
hepatocytes.
We next mapped the human SREBP-1c promoter and identi-
fied the element responsible for AMPKaction. The transcriptional
activation of different lengths of wild-type SREBP-1c promoters
(1470/+90 and 257/+90) was markedly inhibited by polyphe-
nols in HepG2 cells. Disruption of the SRE motif in the same
promoter (257/+90) diminished the basal transcription and pre-
vented the further decrease caused by AMPK activators (Fig-
ure 5C). As shown in Figures 5D–5G, DN-AMPK overexpression
Figure 6. AMPK Catalytic a Subunit Associates with the Precursor and Nuclear Forms of SREBP-1
(A) AMPKa1 or a2 subunit physically associates with endogenous SREBP-1 precursor in HEK293T cells.
(B) GST or GST-AMPKa1 was transiently transfected into HEK293T cells and purified with GSH Sepharose beads. The precipitates and lysates were individually
immunoblotted with antibodies against SREBP-1 or GST.
(C) Endogenous AMPKa subunit interacts with nuclear SREBP-1c. GST or GST-nuclear SREBP-1c was transfected into HEK293T cells and purified by GST
pull-down.
(D) The active form of AMPK preferentially interacts with endogenous SREBP-1 precursor. HEK293T cells were transfected with FLAG-AMPKa1, wild-type,
constitutive active (CA), or dominant-negative (DN) mutants.
(E) AMPK activation by resveratrol enhances the association between AMPKa and SREBP-1 precursor. HEK293T cells were transfected with myc-tagged
wild-type AMPKa1 and treated with resveratrol (10 mM, 16 hr).
(F) AMPK activation by S17834 decreases the cleavage processing of the myc-tagged SREBP-1c precursor in transfected HEK293T cells.
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activity of SREBP-1c and FAS and abrogated the inhibitory effect
of resveratrol on the autoloop regulation. These data depict that
the SRE motif is responsible for AMPK-dependent suppression
of SREBP-1c autoregulation and FAS transcription. Importantly,
the dominant-negative SREBP-1c (DN-SREBP-1c) abolished the
ability of AICAR and resveratrol to suppress endogenous
SREBP-1c-mediated transcription of FAS promoter, although it
did not affect the basal FAS-Luc activity. Moreover, CA-AMPK
repressed the ability of overexpressed nuclear SREBP-1c to
induce FAS gene transcription. Conversely, DN-SREBP-1c
counteracted the inhibitory effect of CA-AMPKa1. The results
further suggest that SREBP-1c is required for AMPK to suppressCFAS transcription through the SRE motif. Similarly, resveratrol
suppressed nuclear SREBP-2-induced transcriptional activation
of SRE-containing target genes including 4XSRE-Luc and LDLR-
Luc reporter genes, comparable to the effect of resveratrol on
SREBP-1c promoter (Figures S5D–S5F). These data reveal that
AMPK inhibits nuclear SREBP-1c and -2 transcriptional activities
by interfering with the feed-forward regulation of their own genes
and target gene regulation in an SRE-dependent manner.
AMPK Interacts with the Precursor and Nuclear Forms
of SREBP-1c or SREBP-2
We hypothesized that AMPK might downregulate SREBP
activity through protein interaction and/or phosphorylation. Asell Metabolism 13, 376–388, April 6, 2011 ª2011 Elsevier Inc. 383
Cell Metabolism
Phosphorylation and Suppression of SREBP by AMPKshown in Figures 6A–6E, when myc-tagged AMPKa1 or -a2 was
immunoprecipitated, endogenous SREBP-1 precursor was
present in the complex with AMPKa1 or -a2. AMPKa1 was
also detected in reciprocal coimmunoprecipitation of SREBP-1
precursor (Figure S4A). GST pull-down experiments and immu-
noblotting analysis revealed that endogenous SREBP-1
precursor was detected in transfected and purified GST-
AMPKa1. Moreover, endogenous AMPKa2 was coimmunopre-
cipitated in overexpressed nuclear SREBP-1c. The data indicate
that AMPKa subunit binds not only to the SREBP-1c precursor
but also to its nuclear form. Despite varying expression of trans-
fected wild-type AMPKa1, CA-AMPK and DN-AMPK mutants
was unavoidable, and the lowest expression of CA-AMPK
showed the greatest amount of the binding to SREBP-1c
precursor, indicating that the active AMPK form preferentially
associates with the SREBP-1 precursor. The notion that the
interaction between AMPKa and SREBP-1 largely depends on
AMPK activation was emphasized by the observation that
AMPK activation by resveratrol enhanced the association of
these two proteins. Furthermore, the strong association between
AMPK and SREBP-2 precursor was present in transfected cells
and in normal LDLR/ mouse livers (Figures S5A and S5B).
Together, AMPKa subunit physically interacts with the precursor
and nuclear forms of SREBP-1c or -2 isoforms.
A proteasome inhibitor, ALLN, was shown to block the rapid
degradation of nuclear fragments of SREBP and ATF6, another
ER protein (Ye et al., 2000). This allows us to assess SREBP-1
proteolysis, which is barely affected by the autoregulation and
degradation of endogenous nuclear SREBP. This cleavage
assay showed that AMPK activation by S17834 inhibited
cleavage processing of exogenous myc-tagged SREBP-1c in
the presence of ALLN, as reflected by a decrease in the nuclear
form derived from overexpressed myc-SREBP-1 with a corre-
sponding increase in its precursor (Figure 6F). The findings
support a proposed model, in which the binding of AMPK to
SREBP-1c precursor may cause a conformational change to
retain SREBP-1c in the ER and to decrease the cleavage
processing.
AMPK Directly Phosphorylates SREBP-1c at Ser372
In Vitro and In Vivo
In vitro AMPK kinase assays were performed using recombinant
SREBP-1c or -2 as a substrate in the presence of ATP, as
described previously (Inoki et al., 2003; Gwinn et al., 2008). As
shown in Figures 7A–7C, wild-type nuclear forms of SREBP-1c
and SREBP-2 purified from transfected HEK293T cells were
directly and potently phosphorylated by purified active AMPK
(Figure S5C). We further searched AMPK recognition consensus
sites on the human SREBP-1c sequence (Gwinn et al., 2008) and
found two putative AMPK sites, Ser336 and Ser372, both of
which were present in the N-terminal region of SREBP-1c (Fig-
ure S4B). The mutation of S372A, but not of S336A, eliminated
AMPK-induced phosphorylation of SREBP-1c, as visualized by
32P-autoradiography and by immunoblots with a newly gener-
ated phospho-specific Ser372 antibody, indicating that Ser372
is specifically phosphorylated by AMPK in vitro. Moreover,
Ser372 phosphorylation was enhanced by phenformin, which
activates AMPK by inhibiting mitochondrial complex 1 inhibitor
(Hawley et al., 2010), and the phosphorylation was ablated384 Cell Metabolism 13, 376–388, April 6, 2011 ª2011 Elsevier Inc.by the nonphosphorylatable S372A mutant in HEK293T cells.
Moreover, AMPK activation by resveratrol increased Ser372
phosphorylation of ectopically expressed precursor and nuclear
forms of SREBP-1c in HEK293T cells (Figures S4C and S4D). To
further characterize AMPK as an upstream kinase that physio-
logically phosphorylates endogenous SREBP-1c, we found
that phosphorylation of endogenous SREBP-1c and ACC was
stimulated by AMPK activators in AMPK+/+ MEFs, but not in
AMPK/ MEFs.
Ser372 Phosphorylation Is Required
for AMPK-Dependent Suppression of SREBP-1c
Function in Hepatocytes
As shown in Figures 7D and 7E, enhanced Ser372 phosphoryla-
tion by AMPK activators decreased nuclear SREBP-1c-induced
transcription of FAS promoter in AMPK+/+ MEFs, and the
decrease was abolished in AMPK/ MEFs. Moreover, the
amount of nuclear form derived from myc-tagged wild-type
SREBP-1c was largely reduced by S17834, accompanied by
a corresponding increase of precursor in the presence of
ALLN. Conversely, the S372A mutant abolished the effect of
S17834 to decrease SREBP-1c proteolytic processing. Consis-
tent with the accumulated nuclear form of the S372Amutant, the
basal promoter activity of SREBP-1c and FAS was increased in
the S372A mutant. The S372A mutant strongly diminished the
inhibitory effect of polyphenols on SREBP-1c promoter activity
(Figure 7F and Figure S4F). The results indicate that AMPK, via
Ser372 phosphorylation, inhibits SREBP-1c cleavage process-
ing, thereby blocking lipogenic gene transcription. To define
whether AMPK-dependent SREBP-1c phosphorylation is phys-
iologically relevant, we found that the ability of S17834-mediated
AMPKactivation to phosphorylate and inactivate SREBP-1cwas
abolished by DN-AMPK in hepatocytes under high glucose
conditions (Figure 7G). Furthermore, Ser372 phosphorylation
was impaired by AMPK inhibition in the liver of insulin-resistant
LDLR/ mice and was restored by S17834 administration (Fig-
ure 7H and Figure S4G). Taken together, phosphorylation and
inactivation of SREBP-1c by AMPK may explain the salutary
effects of AMPK activators on hepatic steatosis, hyperlipidemia,
and atherosclerosis associated with insulin resistance.
DISCUSSION
This study demonstrates that AMPKa specifically binds to and
directly phosphorylates SREBP-1c and SREBP-2. Ser372 phos-
phorylation of SREBP-1c by AMPK may contribute to the ability
of polyphenols and metformin to inhibit the proteolytic cleavage
and nuclear translocation of SREBP-1c in hepatocytes under
high glucose plus insulin conditions, thereby preventing its
autoregulation and transcription of target lipogenic genes. This
link is likely to hold true in vivo, as hepatic AMPK activation by
S17834 also stimulates Ser372 phosphorylation, suppresses
the cleavage and transcriptional activity of SREBP-1c and -2,
and lowers hepatic and plasma triglyceride and cholesterol
levels in diet-induced insulin-resistant LDLR/ mice. AMPK-
dependent phosphorylation and inactivation of SREBP may
represent a molecular mechanism by which AMPK activators
ameliorate insulin resistance, hepatic steatosis, dyslipidemia,
and atherosclerosis (Figure 7I).
Figure 7. SREBP-1c Is a Direct Target of AMPK
(A) Active AMPK phosphorylates human SREBP-1c at Ser372 in vitro. Purified recombinant GST-tagged nuclear forms of SREBP-1c, wild-type (WT), and the
mutations of S372A or S336A, from transfected HEK293T cells, were incubated with purified rat AMPK in the presence of [32P]-ATP and 100 mMof ATP and AMP
at 30C for 30min. Phosphorylation of SREBP-1cwas visualized by 32P-autoradiography or by immunoblots with phospho-specific Ser372 antibody in the in vitro
kinase assay.
(B) AMPK activation by phenformin specifically stimulates Ser372 phosphorylation of SREBP-1c. HEK293T cells expressing GST-tagged human full-length
SREBP-1c, wild-type (WT), or S372A mutant, were treated with phenformin (5 mM) for 1 hr. Total cell lysates were immunoblotted with phospho-specific Ser372
and total SREBP-1 antibodies.
(C) AMPK is required for Ser372 phosphorylation in response to polyphenols and AICAR. AMPK+/+ or AMPK a1/a2 double knockout (AMPK/) MEFs were
treated with AMPK activators for 1 hr.
(D) AMPK-deficient cells exhibit the inability of AMPK activators to repress autoregulation of nuclear SREBP-1c. AMPK+/+ and AMPK/ MEFs were
cotransfected with the plasmids encoding nuclear SREBP-1c and FAS promoter and treated with AMPK activators for 16 hr. Bars represent the mean ± SEM, n =
3–4. *p < 0.05, versus untreated group.
(E) Ser372 phosphorylation of SREBP-1c is required for the inhibition of cleavage of SREBP-1c cleavage in response to S17834 in HEK293T cells.
(F) The mutation of full-length SREBP-1c S372A enhances the basal transcription of SREBP-1c promoter (257/+90) and abrogates the suppression of
SREBP-1c gene transcription in response to AMPK activators in HepG2 cells. Bars represent the mean ± SEM, n = 4–5.*p < 0.05, versus untreated group.
(G) DN-AMPK diminishes polyphenol-induced phosphorylation of SREBP-1c in primary mouse hepatocytes under high-glucose conditions.
(H) AMPK activation by S17834 counteracts impaired Ser372 phosphorylation of SREBP-1c precursor in the liver of insulin-resistant LDLR/ mice.
(I) Proposed model of the phosphorylation regulation of SREBP-1c and -2 by AMPK in the liver: potential therapeutic implication in hepatic steatosis, insulin
resistance, and risk of atherosclerosis.
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Phosphorylation and Suppression of SREBP by AMPKAMPK Inhibits In Vitro Lipogenesis in Hepatocytes
through the Downregulation of the Cleavage
Processing and Transcriptional Activity of SREBP
To support the hypothesis that AMPK is an upstream kinase that
negatively regulates hepatic SREBP activity, we demonstrated
that impaired hepatic AMPK signaling caused by HFHS feeding
was restored by S17834, as was previously seen in S17834-
treated type 1 diabetic mice (Zang et al., 2006). Importantly,
AMPK activation by S17834 prevented increased proteolytic
processing of SREBP-1c and -2 and enhanced expression of
their own and target genes (ACC1, FAS, SCD1, HMGCR,
and HMGCS) in the liver of insulin-resistant mice. Moreover,
AMPK was sufficient and necessary for the suppression of
SREBP-1 cleavage and lipogenic gene expression in response
to polyphenols and metformin in hepatocytes, which may
explain their beneficial effects on aberrant triglyceride/choles-
terol metabolism, hepatic steatosis, and insulin resistance
related to obesity.
AMPK activation by S17834 regulates triglyceride and
cholesterol metabolism in HFHS-fed LDLR/ mice at least
partially through the downregulation of SREBP-1c and -2 pro-
cessing. These animals share some features with SCAP
knockout mice (Matsuda et al., 2001) and with transgenic
mice overexpressing Insig-1 in the liver (Engelking et al.,
2004), where the amounts of both nuclear SREBP-1 and -2
decline, due to the interruption of proteolytic cleavage of their
precursor. Since SCAP/Insig plays a key role in sterol-mediated
negative feedback regulation of SREBP, it would be of interest
to further determine whether SCAP/Insig mediates the effect of
AMPK on SREBP processing.
This study indicates that AMPK functions as a potential kinase
that also controls SREBP-1c and SREBP-2 transcriptional
activity through an autoloop regulation via a SRE motif-depen-
dent mechanism. The deletion analysis of SREBP-1c promoter
showed that the activity of wild-type SREBP-1c promoter, but
not of SRE deletion promoter, was repressed by AMPK activa-
tors. The conclusion that the inhibition of lipogenesis by AMPK
is dependent on SREBP-1c is strengthened by our findings
that the effect of CA-AMPK to repress FAS promoter activity
was diminished by DN-SREBP-1c. Similarly, AMPK activity by
polyphenols also inhibits SREBP-2 transcriptional activity, as
evidenced by decreased nuclear SREBP-2-induced autoregula-
tion and repressed transcription of the LDLR promoter in
response to resveratrol.
AMPK-Dependent Inhibition of SREBP in the Liver
Attenuates Hyperlipidemia and Atherosclerosis
Associated with Insulin Resistance
As the disruption of SREBP-1 reduces hepatic expression
of lipogenic genes and ameliorates fatty liver in Lepob/ob mice
(Yahagi et al., 2002), suppression of SREBP-mediated lipogen-
esis by AMPK may be responsible for polyphenols to improve
hepatic steatosis in diet-induced insulin-resistant mice. This
underlying mechanism also contributes to an antiatherogenic
lipoprotein distribution, characterized by decreased total
cholesterol and VLDL/LDL cholesterol levels, in S17834-treated
diabetic LDLR/ mice with the blockade of VLDL/LDL clear-
ance, which is consistent with decreased hepatic SREBP-2
processing and HMGCS and HMGCR expression. It is worth386 Cell Metabolism 13, 376–388, April 6, 2011 ª2011 Elsevier Inc.noting that in a state of nutrient deprivation, protein levels of
LDL receptor, an important regulator of plasma LDL, are not
reduced, despite decreased mRNA levels of LDL receptor.
This is likely due to the concomitant reduction of PCSK9, a potent
degrader of LDL receptor protein, which is also a SREBP-1c
target (Costet et al., 2006). Thus, we suspect that inhibition of
SREBP by AMPK would reduce mRNA levels of cholesterolo-
genic genes and LDL receptor and also lower plasma cholesterol
levels in wild-type mice, independently of LDLR deficiency. This
possibility is supported by the recent study that betulin, which
inhibits SREBP cleavage by promoting the SCAP/Insig interac-
tion, can reduce serum cholesterol levels in both C57BL/6J
mice and LDLR/ mice (Tang et al., 2011).
The present study provides additional evidence that
decreased atherosclerotic lesions in insulin-resistant LDLR/
mice are largely attributed to the lipid-lowering effect of
S17834, consistent with reduced atherogenesis seen in
S17834-treated type 1 diabetic LDLR/ mice (Zang et al.,
2006). In addition, the potential local effects of S17834 on
vascular cells in diabetic LDLR/ mice are evidenced by
improved local vascular inflammation, as indicated by decreased
VCAM-1 expression in the atherosclerotic lesion-prone region of
the aortic arch. The role of polyphenols in regulating atherogenic
factors is also emphasized by the fact that S17834 protects
against cytokine-induced VCAM-1 in endothelial cells (Cayatte
et al., 2001). These results indicate that SREBP suppression by
S17834 or by other potential AMPK activators inhibits acceler-
ated atherogenesis associated with metabolic syndrome via
a mechanism that can improve dyslipidemia, prevent local
vascular dysfunction, or both.
AMPK Suppresses SREBP Activity by Enhancing
these Two Protein Interaction and Directly
Phosphorylating SREBP
One of the most important findings is that SREBP-1c and -2 are
conserved substrates of AMPK. The AMPKa subunit physically
interacts with the precursor and nuclear forms of SREBP-1 or
SREBP-2, and this interaction is stimulated by CA-AMPK.
Recent studies on the crystal structure of AMPKa1 subunit indi-
cate that AMPKa1 is held in an inactive conformation through an
interaction between the autoinhibitory domain and the kinase
domain. When elevated AMP is bound to the g subunit, the inhib-
itory domain of the a1 subunit is released from the kinase
domain. This results in an active conformation of AMPK, which
allows the upstream kinases, such as LKB1, to phosphorylate
Thr172 on AMPKa (Young, 2009). A specific active conformation
of AMPKamay also enable its substrates to be more accessible
to the kinase domain of AMPKa. This possibility is supported by
our findings that the active AMPKa subunit preferentially bound
to and phosphorylated SREBP-1c and -2.
In vitro kinase assays and mutagenic studies provide
biochemical evidence that Ser372 on SREBP-1c is amajor phos-
phorylation site of AMPK. Although AMPK may phosphorylate
additional sites that contribute to SREBP inhibition, Ser372
phosphorylation is sufficient and required for the suppression
of SREBP-1c-dependent lipogenesis in response to polyphenols
and metformin, since the ability of AMPK activators to suppress
SREBP-1 cleavage and autoregulation and prevent FAS
gene transcription was abolished by the S372A mutant. The
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is evidenced by the fact that SREBP-1c phosphorylation was
diminished by AMPK impairment in insulin-resistant LDLR/
mice and stimulated by AMPK activation in S17384-treated
mice. Because elevated cleavage and amounts of gene expres-
sion of hepatic SREBP-2 in insulin-resistant mice can be
prevented by S17834 in vivo, it is conceivable that a similar phos-
phorylation mechanism may be involved. Future studies are
needed to identify an AMPK phosphorylation site on SREBP-2.
The SREBP family was previously shown to be negatively regu-
lated by other protein kinases. PKA inhibits SREBP-1c transcrip-
tional activity through the phosphorylation of nuclear SREBP-1c
at Ser314 without altering cleavage processing (Lu and Shyy,
2006). GSK3 directly phosphorylates Thr426/Thr420 on
SREBP-1a and Ser433 on SREBP-2, which mediates Fbw7-
induced ubiquitination and degradation of their nuclear forms
(Sundqvist et al., 2005). Thus, the multilayered control of SREBP
by protein kinases may contribute to the hepatic lipid homeo-
stasis under physiological and pathological conditions.
The precise mechanism for the dysregulation of SREBP family
in type 2 diabetes has not yet been established. This study
indicates that AMPK inhibition may result in elevated cleavage
and transcription of hepatic SREBP-1c and -2 in insulin-resistant
mice. It is likely that other nutrient sensors controlled by AMPK,
such as downstream kinases like mTORC1, or concurrent regu-
lation of SIRT1 and AMPK (Hou et al., 2008), may also modulate
SREBP-dependent lipid synthesis in type 2 diabetes. During the
revision period, Goldstein and colleagues have reported that
mTORC1 plays an essential role in regulating hyperinsulinemia-
induced SREBP-1c and hepatic lipogenesis (Li et al., 2010).
SIRT1 also deacetylates and inhibits nuclear SREBP-1c and -2
in response to fasting (Walker et al., 2010).
In conclusion, the current study identifies a biochemical mech-
anism of SREBP regulation by AMPK, and reveals the functional
importance of this phosphorylation regulation in the pathogen-
esis of insulin resistance and in the therapeutic effects of
AMPK activators, such as polyphenols and metformin, on type
2 diabetes and its vascular complications.EXPERIMENTAL PROCEDURES
Animal Model and Diet
Male LDLR/ mice on C57BL/6J background at the age of 8 weeks were
purchased from Jackson Laboratory (Bar Harbor, ME). Mice were fed on
a HFHS diet and HFHS supplemented with S17834 (130 mg/kg/day) for
16 weeks. These procedures were approved by the Boston University Medical
Center Institutional Animal Care and Use Committee.
Liver Histological and Immunohistochemical Analysis
Livers were fixed in 10%phosphate-buffered formalin acetate at 4Covernight
and embedded in paraffin wax. Paraffin sections (5 mm) were cut and mounted
on glass slides for H&E staining. Cryosections of livers were stained by oil red
O and counterstained with hematoxylin to visualize the lipid droplets. Immuno-
histochemistry of liver sections was also performed as previously described
(Zuccollo et al., 2005).
Assessment of Aortic Atherosclerosis and Immunohistochemistry
The whole aortae were collected and stained by oil red O (60% solubilized
in propylene glycol) for en face analysis of atherosclerosis lesion area. The fixa-
tion and preparation of the aortae and the quantification of atherosclerotic
lesions were performed as previously described (Zuccollo et al., 2005).CCell Treatment
Human HepG2 hepatocytes, human embryonic kidney 293 cells (HEK293T),
and AMPK+/+ or AMPK a1/a2 double knockout (AMPK/) MEFswere cultured
and treated as previously described (Zang et al., 2004, 2006; Hou et al., 2008;
Laderoute et al., 2006).
Statistical Analysis
Values are expressed as mean ± SEM. Statistical significance was evaluated
using the unpaired two-tailed t test and among more than two groups by anal-
ysis of one-way ANOVA. Differences were considered significant at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, two tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article at doi:10.1016/j.cmet.2011.03.009.
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